Search Results

You are looking at 71 - 80 of 590 items for :

  • pharmacokinetics x
Clear All
Open access

Dragana Dragas Milovanovic, Ivan Radosavljevic, Marija Radovanovic, Jasmina R. Milovanovic, Slobodan Obradovic, Slobodan Jankovic, Dragan Milovanovic and Natasa Djordjevic

, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014; 37C:59-70. 6. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50(1):1-23. 7. Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011; 21(12):906-10. 8. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol

Open access

Vаnja Dzambazovska-Trajkovska, Jordan Nojkov, Adrijan Kartalov, Biljana Kuzmanovska, Tatjana Spiroska, Gjorgji Trajkovski, Nadica Geshkovska-Matevska and Aleksandar Dimovski

:543-554. 15. Drewe J, Ball HA, Beglinger C, et al. Effect of p-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000; 50: 237-246. 16. Skarke C, Jarrar M, Erb K, et al. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74: 303-311. 17. Kharasch ED, Hoffer C, Altuntas TG, Whittington D. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl

Open access

Vipul P. Patel, Hardik A. Lakkad and Kalpesh Chhotalal Ashara

improved dosing schedule for ivermectin as a microfilaricidal agent against onchocerciasis. Acta Trop 1997;68(3):269-75. 5. Camargo JA, Sapin A, Nouvel C, et al. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physicochemical characterization. Drug Dev Ind Pharm 2013;39(1):146-55. 6. Canga AG, Sahagun Prieto AM, Diez Liebana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J 2008;10(1):42-6. 7. Chaudhari PD, Motewar PP, Sherekar

Open access

Ioan Țilea, Daniela Saveta Popa, Timea Szakács Xantus, Daniela Primejdie, Bianca Grigorescu, Brîndușa Țilea, Andreea Elena Bocicor and Andreea Varga

.1097/ ALN.0b013e318289bcba 9. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anesthesia and antithrombotic agents: recommendations of the European society of Anaesthesiology. Eur J Anaesthesiol. 2010 Dec;27(12):999-1015. DOI: 10.1097/ EJA.0b013e32833f6f6f 10. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb;75

Open access

Pattarachai Kiratisin

methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2006; 54:231-6. 11. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006; 119 Suppl 1:S20-S8. 12. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008; 61:621-8. 13. Kahlmeter G. Breakpoints for intravenously used cephalosporins in

Open access

Kreetachon Veerakikosol, Pajaree Chariyavilaskul, Natavudh Townamchai and Supeecha Wittayalertpanya

interindividual variability is found in tacrolimus pharmacokinetics, particularly in the dosage required to achieve target blood concentrations [ 2 ]. The recommended C 0 levels of tacrolimus are 10 to 20 ng/mL during the first 3 months after transplantation (induction phase), followed by C 0 levels of 5 to10 ng/mL during the maintenance phase. Significant toxicity is seen with C 0 levels of 15 ng/mL [ 3 ]. Subsequent trials often used for C 0 ranged between 7 to 8 ng/mL in the early post-transplantation period, and 5 to 7 ng/mL during the maintenance phase. An

Open access

Sylwia Borys, Ronza Khozmi, Wiesława Kranc, Artur Bryja, Michal Jeseta and Bartosz Kempisty

. Prozdrowotne właściwości resweratrolu, Nauka Technologia Jakość 2011; 5 (78): 5-15. [21] Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms, Curr. Med. Chem. 2013; 20 (36): 4640-5. [22] Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-dawley rats: the impacts of aqeous solubility, dose escalation, food and repeated dosing on oral bioavailability, J. Pharm. Sci. 2011; 100 (10): 4491-500. [23] Liu Yin MY, Wy X, Zeng M, Zhao Q

Open access

Vanja Dzambazovska-Trajkovska, Jordan Nojkov, Andrijan Kartalov, Biljana Kuzmanovska, Tatjana Spiroska, Redzep Seljmani, Gjorgji Trajkovski, Nadica Matevska-Geshkovska and Aleksandar Dimovski

brain opioid receptor availability in central and peripheral neuropathic pain. Pain. 2007 Jan; 127(1–2): 183–94. 5. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4–33. 51. 6. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457–473. 52. 7. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang’s J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1

Open access

Walter Fröscher, Timo Kirschstein and Johannes Rösche

(Anticonvulsant therapy for brain tumor-related epilepsy). Fortschr. Neurol. Psychiat., 2014, 82: 678-690. Gefroh-Grimes H.A., Gidal B.E.: Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Neurol. Scand., 2016, 133: 4-16. Gerstner T., Teich M., Bell N., Longin E., Dempfle C.-E., Brand J. et al.: Valproate-associated coagulopathies are frequent and variable in children. Epilepsia, 2006, 47: 1136-1143. Glantz M.J., Cole B.F., Forsyth P.A., Recht L.D., Wen P.Y., Chamberlain M.C. et

Open access

Kornkiat Snidvongs, Chutima Rotjanasiriphong, Chantima Phannaso, Supinda Chusakul and Songklot Aeumjaturapat

antihistamines, while astemizole and terfenadine have been removed from the market in most countries because of their potential to the prolong QT interval, and cause serious polymorphic ventricular arrhythmias, such as torsades de pointes [ 3 ]. Various types of H 1 -receptor antagonists have various pharmacokinetic and pharmacodynamics properties. To date, fexofenadine, levocetirizine. and desloratadine are considered third generation antihistamines. Each drug has an advantage over the others. Among these three, desloratadine has the highest affinity for binding receptors